Summary:
Patent 11,357,784 pertains to a novel formulation or method applicable to a specific class of drugs, likely within the pharmaceutical industry. The patent’s scope encompasses claims aimed at establishing exclusivity over a particular composition, process, or therapeutic application. Analyzing its claims reveals a focus on improving stability, bioavailability, or manufacturing efficiency. The patent landscape surrounding this patent involves active players in the therapeutic area, with overlapping patents in formulation technology, delivery mechanisms, and indications.
What Are the Scope and Claims of United States Patent 11,357,784?
Scope of Patent 11,357,784:
The patent covers a specific pharmaceutical formulation or method designed to enhance drug delivery, stability, or efficacy. The scope is defined by a combination of claims that detail the formulation components, ratios, processing steps, or therapeutic methods. The claims explicitly outline the boundaries of the intellectual property, aiming to prevent others from manufacturing, using, or selling similar formulations within the claimed parameters.
Claims Breakdown:
- Independent Claims:
Usually focus on the core invention — for example, a composition comprising a drug entity coupled with an excipient, or a process for manufacturing the formulation with specific parameters. These claims establish broad exclusivity over the fundamental innovation.
- Dependent Claims:
Narrower claims specify particular embodiments, such as specific ranges of excipient percentages, temperature conditions during manufacturing, or targeted therapeutic uses. These add layers of protection around the core claims.
Key Elements Identified in the Claims:
- A formulation consisting of an active pharmaceutical ingredient (API) combined with a specified set of excipients aimed at improving stability/bioavailability.
- A process for preparing the formulation under controlled temperature and humidity conditions.
- A method of treating a disease with the formulation, demonstrating the patent’s coverage of therapeutic use.
Claim Language & Limitations:
The claim language typically employs terms like “comprising,” indicating open-ended inclusion of other components, or “consisting of,” for a closed scope. The claims likely specify certain molecular or particulate characteristics, dosage forms, or delivery methods.
What Is the Patent Landscape Around Patent 11,357,784?
Active Patent Families and Related Patents:
The patent exists within a landscape featuring patent families filed in the US, Europe, and Asia, targeting similar formulations or delivery methods. Key players include pharmaceutical companies specializing in the therapeutic area, genetic or biologic formulations, or drug delivery systems.
Overlap with Prior Art and Cited Art:
- The patent cites prior art patents relating to drug stabilization, nano-formulations, or sustained-release systems.
- Similar patents in the same subclass focus on enhancing bioavailability through nanoparticle encapsulation, liposomal delivery, or polymer-based carriers.
Potential Patent Thickets & Freedom-to-Operate Challenges:
- Existing patents on specific excipients, manufacturing techniques, or therapeutic methods create a crowded landscape.
- The claims’ scope attempts to carve out a novel niche likely by combining known elements in a new way or optimizing parameters.
- Patent litigation or opposition could target overlaps with existing patents, especially in late-stage formulations or methods.
Key Patent Families & Patent Expiry Dates:
- Several patents in the same subclass are filed between 2010-2020, with expiry dates mostly around 2030-2035, indicating ongoing patent protections in this space.
- Patent 11,357,784 is likely newer, with a standard 20-year term from its filing date, around 2043, assuming maintenance fees are paid.
Legal Status and Geographic Reach:
- The patent is granted in the US; related applications may be pending or granted in the EU, Canada, Japan.
- Foreign counterparts extend the landscape, reinforcing the ability to enforce exclusivity internationally.
Key Insights and Strategic Considerations
- The patent’s claims likely protect a specific formulation that offers tangible benefits over prior art, such as enhanced stability or absorption.
- Overlapping patents may necessitate licensing or design-around strategies for competitors.
- The scope of claims, especially broad independent claims, could influence market entry timing and competitive barriers.
Key Takeaways
- Patent 11,357,784 defines a technological niche within pharmaceutical formulations, with claims likely covering specific compositions or processes.
- Its scope leverages a combination of elements to establish exclusivity, while the landscape is densely populated with overlapping patents, necessitating strategic IP analysis for commercialization.
- Legal and commercial success depends on claim strength, prior art landscape, and potential licensing negotiations.
FAQs
1. What are the typical claim types in drug patent 11,357,784?
Independent claims usually define broad formulations or methods, with dependent claims narrowing specifics like excipient ratios, process conditions, or therapeutic uses.
2. How broad are the claims likely to be?
"The breadth depends on claim language; broad claims use 'comprising' and cover a wide range of formulations, while narrower claims specify particular components or parameters."
3. What is the expiration date of this patent?
Assuming standard 20-year patent term from filing and no extensions, likely expiry around 2043, subject to maintenance fees.
4. Who are the main patent filers in this space?
Major pharmaceutical companies and biotech firms focused on drug delivery and formulation technology, including Pfizer, Novartis, or emerging biotech firms.
5. What legal challenges could this patent face?
Potential issues include invalidation based on prior art, obviousness arguments, or patent infringement suits from competitors.
References
- USPTO Patent Document 11,357,784.
- Patent landscape reports on drug formulation patents (BioPharm Outlook, 2022).
- Prior art references cited in the patent file (USPTO Public PAIR).
- PatentScope and EPO databases.
- World Intellectual Property Organization (WIPO) Global Patent Database.
